Stock News in Focus: Codexis (NASDAQ:CDXS)

Codexis (NASDAQ:CDXS) a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement.

The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets, said Codexis President and CEO John Nicols. Casdin has long recognized our technology and leadership capability and, with their latest investment, we have significant financial flexibility to capitalize on a variety of growth opportunities.

The ability to drive performance and economic advantages through the intelligent engineering of enzymes is now a critical capability across a diverse set of end markets, said Eli Casdin, CEO of Casdin Capital. We believe that Codexis is one of the few proven management teams and technology platforms capable of capturing this fast-growing market demand and are excited to catalyze their strategic growth initiatives.stock identified change of 49.88% away from 52-week low price and recently located move of -16.44% off 52-week high price. It has market worth of $1046.59M. CDXS stock has been recorded 1.06% away from 50 day moving average and 3.50% away from 200 day moving average. Moving closer, we can see that shares have been trading 6.74% off 20-day moving average.

Codexis (NASDAQ: CDXS) a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement.

The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets, said Codexis President and CEO John Nicols. Casdin has long recognized our technology and leadership capability and, with their latest investment, we have significant financial flexibility to capitalize on a variety of growth opportunities.

The ability to drive performance and economic advantages through the intelligent engineering of enzymes is now a critical capability across a diverse set of end markets, said Eli Casdin, CEO of Casdin Capital. We believe that Codexis is one of the few proven management teams and technology platforms capable of capturing this fast-growing market demand and are excited to catalyze their strategic growth initiatives. The Healthcare sector company, Codexis noticed change of 0.36% to $19.26 along volume of 349085 shares in recent session compared to an average volume of 313.72K. The stock observed return of 10.37% in 5 days trading activity. The stock was at -1.23% over one month performance. CDXS’s shares are at -1.83% for the quarter and driving a 17.08% return over the course of the past year and is now at 15.33% since this point in 2018. 

 The average volatility for the week at 3.41% and for month was at 3.74%. There are 54.34M shares outstanding and 52.15M shares are floated in market. Right now the stock beta is -0.14. 

Leave a Reply

Your email address will not be published. Required fields are marked *